Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD5718 on Midazolam PK in Healthy Subjects
NCT04492709Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atuliflapon in cardiovascular disease (CVD), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma peak concentration of midazolam at Day 7, Area under plasma concentration-time curve from time zero to infinity of midazolam at Day 7 and 4 more. Started Jul 2020; status: completed.
02
Drugs
atuliflapon
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04492709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492709.